Cargando…
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expand...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Immunologists
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049582/ https://www.ncbi.nlm.nih.gov/pubmed/32158596 http://dx.doi.org/10.4110/in.2020.20.e8 |